Outcomes related to respiratory syncytial virus with an abbreviated palivizumab regimen in children with congenital heart disease: a descriptive analysis.

Autor: Claydon J; Children's & Women's Health Centre of British Columbia (Claydon, Popescu, Christopherson, Human, Solimano, Lavoie); Divisions of Neonatology (Popescu, Shaiba, Solimano, Lavoie) and Cardiology (Human), Department of Pediatrics, University of British Columbia; British Columbia Children's Hospital Research Institute (Popescu, Human, Lavoie), Vancouver, BC; Victoria General Hospital (Taylor), Victoria, BC; University of Toronto (Shaiba), Toronto, Ont., Popescu CR; Children's & Women's Health Centre of British Columbia (Claydon, Popescu, Christopherson, Human, Solimano, Lavoie); Divisions of Neonatology (Popescu, Shaiba, Solimano, Lavoie) and Cardiology (Human), Department of Pediatrics, University of British Columbia; British Columbia Children's Hospital Research Institute (Popescu, Human, Lavoie), Vancouver, BC; Victoria General Hospital (Taylor), Victoria, BC; University of Toronto (Shaiba), Toronto, Ont., Shaiba L; Children's & Women's Health Centre of British Columbia (Claydon, Popescu, Christopherson, Human, Solimano, Lavoie); Divisions of Neonatology (Popescu, Shaiba, Solimano, Lavoie) and Cardiology (Human), Department of Pediatrics, University of British Columbia; British Columbia Children's Hospital Research Institute (Popescu, Human, Lavoie), Vancouver, BC; Victoria General Hospital (Taylor), Victoria, BC; University of Toronto (Shaiba), Toronto, Ont., Christopherson C; Children's & Women's Health Centre of British Columbia (Claydon, Popescu, Christopherson, Human, Solimano, Lavoie); Divisions of Neonatology (Popescu, Shaiba, Solimano, Lavoie) and Cardiology (Human), Department of Pediatrics, University of British Columbia; British Columbia Children's Hospital Research Institute (Popescu, Human, Lavoie), Vancouver, BC; Victoria General Hospital (Taylor), Victoria, BC; University of Toronto (Shaiba), Toronto, Ont., Human D; Children's & Women's Health Centre of British Columbia (Claydon, Popescu, Christopherson, Human, Solimano, Lavoie); Divisions of Neonatology (Popescu, Shaiba, Solimano, Lavoie) and Cardiology (Human), Department of Pediatrics, University of British Columbia; British Columbia Children's Hospital Research Institute (Popescu, Human, Lavoie), Vancouver, BC; Victoria General Hospital (Taylor), Victoria, BC; University of Toronto (Shaiba), Toronto, Ont., Taylor R; Children's & Women's Health Centre of British Columbia (Claydon, Popescu, Christopherson, Human, Solimano, Lavoie); Divisions of Neonatology (Popescu, Shaiba, Solimano, Lavoie) and Cardiology (Human), Department of Pediatrics, University of British Columbia; British Columbia Children's Hospital Research Institute (Popescu, Human, Lavoie), Vancouver, BC; Victoria General Hospital (Taylor), Victoria, BC; University of Toronto (Shaiba), Toronto, Ont., Solimano A; Children's & Women's Health Centre of British Columbia (Claydon, Popescu, Christopherson, Human, Solimano, Lavoie); Divisions of Neonatology (Popescu, Shaiba, Solimano, Lavoie) and Cardiology (Human), Department of Pediatrics, University of British Columbia; British Columbia Children's Hospital Research Institute (Popescu, Human, Lavoie), Vancouver, BC; Victoria General Hospital (Taylor), Victoria, BC; University of Toronto (Shaiba), Toronto, Ont., Lavoie PM; Children's & Women's Health Centre of British Columbia (Claydon, Popescu, Christopherson, Human, Solimano, Lavoie); Divisions of Neonatology (Popescu, Shaiba, Solimano, Lavoie) and Cardiology (Human), Department of Pediatrics, University of British Columbia; British Columbia Children's Hospital Research Institute (Popescu, Human, Lavoie), Vancouver, BC; Victoria General Hospital (Taylor), Victoria, BC; University of Toronto (Shaiba), Toronto, Ont. plavoie@cw.bc.ca.
Jazyk: angličtina
Zdroj: CMAJ open [CMAJ Open] 2019 Feb 18; Vol. 7 (1), pp. E88-E93. Date of Electronic Publication: 2019 Feb 18 (Print Publication: 2019).
DOI: 10.9778/cmajo.20180167
Abstrakt: Background: It has been hypothesized that 4 doses of palivizumab, a neutralizing monoclonal antibody against respiratory syncytial virus (RSV), administered during a fixed-date RSV season may reduce hospital admissions comparably to the standard 5-dose schedule. We report outcomes in children with congenital heart disease approved to receive this 4-dose palivizumab schedule in British Columbia.
Methods: We performed a population-based descriptive cohort analysis of all 406 approved palivizumab courses over 4 seasons (2012/13 to 2015/16) in 325 children with hemodynamically significant congenital heart disease enrolled in the British Columbia RSV Immunoprophylaxis Program. The primary outcome was in-season hospital admission for potential RSV-related lower respiratory tract infection (LRTI). Secondary outcomes include timing of admission in relation to dosing. Analysis was by intention-to-treat.
Results: Of the 406 approved palivizumab courses, 391 were administered. In 33 cases (8.4%), an additional dose was given immediately after cardiac bypass surgery. There were 17 RSV-confirmed hospital admissions (median age of children 5.9 mo [interquartile range 4-10 mo]) and 8 admissions in which the child was not tested for RSV, for a maximum of 25 potential RSV-related admissions (6.2 per 100 approvals [95% confidence interval 4.0-9.0]). Twenty-four (96%) of the 25 admissions occurred within the 4-dose palivizumab dosing period, and the remaining admission occurred 52 days after the fourth dose. Sixty-four (72%) of 89 admissions were RSV-negative; the baseline clinical characteristics of these children were not different from those of children with RSV-confirmed admissions.
Interpretation: In infants with hemodynamically significant congenital heart disease, a 4-dose fixed-date palivizumab schedule over a 6-month season provided seasonal protection comparable to that in a clinical trial involving a standard 5-dose schedule. Because RSV was responsible for only 19% of admissions for LRTI in our cohort, it is critical to continue to emphasize other preventive measures, including family education toward proper hand hygiene, breast-feeding and limiting infectious exposures in children at high risk.
Competing Interests: Competing interests: None declared.
(Copyright 2019, Joule Inc. or its licensors.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje